These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 29713852)

  • 1. Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
    Bays HE; Rosenson RS; Baccara-Dinet MT; Louie MJ; Thompson D; Kees Hovingh G
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):181. PubMed ID: 29713852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
    Bays HE; Leiter LA; Colhoun HM; Thompson D; Bessac L; Pordy R; Toth PP
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
    Bays HE; Rosenson RS; Baccara-Dinet MT; Louie MJ; Thompson D; Hovingh GK
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):175-180. PubMed ID: 29627892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.
    Farnier M; Gaudet D; Valcheva V; Minini P; Miller K; Cariou B
    Int J Cardiol; 2016 Nov; 223():750-757. PubMed ID: 27573600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT).
    Koh KK; Nam CW; Chao TH; Liu ME; Wu CJ; Kim DS; Kim CJ; Li I; Li J; Baccara-Dinet MT; Hsiao PJ; Chiang CE
    J Clin Lipidol; 2018; 12(1):162-172.e6. PubMed ID: 29153823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.
    Robinson JG; Rosenson RS; Farnier M; Chaudhari U; Sasiela WJ; Merlet L; Miller K; Kastelein JJ
    J Am Coll Cardiol; 2017 Feb; 69(5):471-482. PubMed ID: 28153102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
    Moriarty PM; Parhofer KG; Babirak SP; deGoma E; Duell PB; Hohenstein B; Ramlow W; Simha V; Steinhagen-Thiessen E; Thompson PD; Vogt A; von Stritzky B; Du Y; Manvelian G
    J Clin Lipidol; 2016; 10(3):627-34. PubMed ID: 27206951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years.
    Farnier M; Colhoun HM; Sasiela WJ; Edelberg JM; Asset G; Robinson JG
    J Clin Lipidol; 2017; 11(4):986-997. PubMed ID: 28693998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.
    Roth EM
    Future Cardiol; 2016 Mar; 12(2):115-28. PubMed ID: 26785741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).
    Gaudet D; Watts GF; Robinson JG; Minini P; Sasiela WJ; Edelberg J; Louie MJ; Raal FJ
    Am J Cardiol; 2017 Jan; 119(1):40-46. PubMed ID: 27793396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Taskinen MR; Del Prato S; Bujas-Bobanovic M; Louie MJ; Letierce A; Thompson D; Colhoun HM
    Atherosclerosis; 2018 Sep; 276():124-130. PubMed ID: 30059843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.
    Catapano AL; Lee LV; Louie MJ; Thompson D; Bergeron J; Krempf M
    Sci Rep; 2017 Apr; 7():45788. PubMed ID: 28374849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
    Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
    J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
    Gaudet D; Kereiakes DJ; McKenney JM; Roth EM; Hanotin C; Gipe D; Du Y; Ferrand AC; Ginsberg HN; Stein EA
    Am J Cardiol; 2014 Sep; 114(5):711-5. PubMed ID: 25060413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
    Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
    Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
    Koren MJ; Roth EM; McKenney JM; Gipe D; Hanotin C; Ferrand AC; Wu R; Dufour R
    Postgrad Med; 2015 Mar; 127(2):125-32. PubMed ID: 25609019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
    Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.